Cipla, Hetero Drugs deal

Hetero granted Cipla non-exclusive commercialization rights to Actorise darbepoetin alfa, a biosimilar of Aranesp darbepoetin alfa, in India, where Cipla launched the product to treat anemia caused by chronic kidney disease (CKD). Hetero said a 25 µg pre-filled syringe of the drug costs Rs1,550 ($24.90) and a 40 µg syringe costs Rs2,200 ($36.52). The companies declined to disclose financial terms of the deal. ...